ziprasidone mesylate injection / Generic mfg. - LARVOL DELTA

From IM to Empathy: A Structured, Low-Cost De-escalation Protocol to Reduce Restraint of Autistic Youth in the Emergency Department (AAP-NCE 2025) - "After a case involving overnight IM ziprasidone administration to a young teen with autism and no prior aggression, we launched a quality improvement initiative to disrupt this cycle.A multi-disciplinary team including pediatrics, pharmacy, emergency medicine, psychiatry and nursing adapted and utilized a rapid-response, low-stimulation protocol... Following implementation of the de-escalation protocol, significant reductions in IM medications and security interventions have occurred. Staff confidence improved and patient escalations have been reduced. In one case, using the protocol resulted in reduction of IM medication use for an autistic patient by 75% and no subsequent physical restraint or sedation was needed."

Clinical • Anesthesia • Autism Spectrum Disorder • Genetic Disorders • Mood Disorders • Pediatrics • Psychiatry

Efficacy and Safety of Ziprasidone Injection vs Haloperidol Injection for Agitation in Patients with Acute Schizophrenia. (PubMed, Alpha Psychiatry) - P=N/A | "However, ziprasidone exhibited superior characteristics in safety and tolerability, particularly in reducing the incidence of extrapyramidal symptoms. The study was registered at https://www.chictr.org.cn/showproj.html?proj=246996, registration number: ChiCTR2500100002, date of registration: 1 April 2025."

Journal • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry • Psychomotor Agitation • Schizophrenia

The study on the Efficacy and Safety of Ziprasidone Mesylate Injection in the Treatment of Acute Agitation Symptoms in Patients with Schizophrenia (ChiCTR) - P=N/A | N=70 | Completed | Sponsor: Shandong Mental Health Center; Shandong Mental Health Cente

New trial • CNS Disorders • Psychiatry • Schizophrenia

Novel Presentations of Post-Infectious Catatonia: A Case Series (APA 2024) - "Initial trial of low dose Quetiapine exacerbated his symptoms and he began exhibiting new symptoms of catatonia including mutism, withdrawal, poor oral intake, and fluctuation in mentation (BFCRS score 13)...Due to initial concerns for paranoia and internal preoccupation, she was trialed on IM Ziprasidone and Olanzapine with minimal improvement in her symptoms...She was started on scheduled Lorazepam PO or IM in addition to Sertraline and was eventually discharged... This series aims to highlight the heterogeneous presentation and management of post-infectious catatonia in patients with a variety of psychiatric histories. Standard treatment with benzodiazepine and ECT appears to be beneficial. While these cases responded adequately to standard management of catatonia, this series adds to the growing body of literature that describes neuropsychiatric manifestations of COVID-19."

Clinical • CNS Disorders • Depression • General Anxiety Disorder • Infectious Disease • Mental Retardation • Mood Disorders • Novel Coronavirus Disease • Postpartum Depression • Psychiatry

Current Evidence-Based Review of the Evaluation and Management of Pediatric Aggression (AACAP 2023) - "The following classes of medications will be described, along with the evidence guiding their support: antihistamines (1 randomized controlled trial of PRN diphenhydramine vs placebo), benzodiazepines (no studies identified for the use of benzodiazepines for this indication), typical antipsychotics (haloperidol: randomized controlled trial and haloperidol vs lithium), atypical antipsychotics (risperidone: randomized controlled trial on an inpatient unit, 2 randomized controlled trials for the intellectually disabled patients; olanzapine: open-label, prospective study; intramuscular [IM] ziprasidone vs IM olanzapine retrospective chart review; ziprasidone vs IM haloperidol and IM lorazepam), stimulants (randomized controlled trial of methylphenidate extended-release tablets vs methylphenidate using aggression as secondary outcome measure), mood stabilizers (lithium: randomized controlled trial on inpatient unit), and antidepressants (bupropion: 4-site randomized..."

Clinical • Review • Pediatrics • Psychiatry

The safety and efficacy of sequential intramuscular/oral ziprasidone treatment of acute episode in patients with schizophrenia: a multicenter, open-labeled study. (PubMed, BMC Psychiatry) - "Ziprasidone IM demonstrated significant and rapid reduction in agitation, and sequential oral formulation keep stability and continuation of the treatment can further ensure efficacy. Ziprasidone sequential therapy may provide a new approach to acute agitation in schizophrenic patients."

Clinical • Journal • Anesthesia • CNS Disorders • Psychiatry • Schizophrenia

Characterization of the Use of Intramuscular Ziprasidone for Acute Agitation (ASHP 2021) - No abstract available

Evaluation of intramuscular olanzapine and ziprasidone in the medically ill. (PubMed, Ment Health Clin) - "Seventy-four percent of patients received IM ziprasidone and 26% received IM olanzapine. Additionally, their use appeared to be well-tolerated, and no patient developed Torsades de Pointes even when combined with other agents that putatively increase QTc. Given the retrospective, single-center, nonrandomized design of this study, the safety and effectiveness of these parenteral second-generation antipsychotics in common causes of acute agitation should continue to be further evaluated."

Journal • CNS Disorders • Psychiatry

[VIRTUAL] Geriatric emergency medicine maximum (GEM-X) initial dosing quality improvement project (QIP) in a community hospital: review of actual versus recommended initial dosing (ASHP 2020) - " We performed a retrospective chart review based on patients greater than or equal to 65 years old who received at least one dose of haloperidol IV/IM, ziprasidone IM, lorazepam IV, fentanyl IV, or morphine IV in the ED between January 1, 2020 and June 30, 2020. Many of our older patients in the emergency department are exposed to these important medications in excess of the geriatric recommended initial dose. In general, these patients received an average of two times the initial recommended dose. These findings indicate a need for a standardized ED dosing procedure."

Clinical • Review • CNS Disorders

"Voriconazole, Ziprasidone mesylate IM, Maropitant, Aripiprazole IM, Posaconazole IV, Carbamazepine IV, Melphalan IV, Carfilzomib IV, Amiodarone premix" (@dfmunozp)

Ziprasidone in treating bipolar child and adolescent patients: More research is warranted. (PubMed, Bipolar Disord) - "Oral ziprasidone (ziprasidone hydrochloride) has been approved by the U.S. Food and Drug Administration (FDA) in 2001 for the treatment of schizophrenia, and acute manic or mixed episodes associated with bipolar disorder (BPD) with or without psychotic features. Ziprasidone intramuscular (ziprasidone mesylate) is FDA-approved for acute agitation in patients with schizophrenia."

Clinical • Journal

Examining the safety, efficacy, and patient acceptability of inhaled loxapine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. (PubMed, Neuropsychiatr Dis Treat) - "Additionally, inhaled loxapine has comparable efficacy to intramuscular ziprasidone, olanzapine, haloperidol, aripiprazole, and lorazepam, with the added benefit of being non-painful and non-traumatizing. Additionally, the use of inhaled loxapine can be associated with dysgeusia and throat irritation. Inhaled loxapine requires some degree of patient cooperation, and therefore may not be appropriate for all agitated patients."

Clinical • Journal • Review

Literature review and economic evaluation of oral and intramuscular ziprasidone treatment among patients with schizophrenia in China. (PubMed, Gen Psychiatr) - "The average estimated LOS was 29 days with ziprasidone, 33 days with risperidone+benzodiazepine, 32 days with olanzapine, 35 days with haloperidol and 29 days with ECT. Compared with other antipsychotics, the higher medication cost of intramuscular ziprasidone can be offset by savings with shorter hospital stay. The results from this economic analysis were complementary to the findings in the published literature assessing the economic outcomes of oral ziprasidone."

Clinical • HEOR • Journal